Natus Medical Inc (BABY) is Upgraded by Raymond James to Outperform

Natus Medical Inc (BABY) was Upgraded by Raymond James to ” Outperform”. Earlier the firm had a rating of “Mkt Perform ” on the company shares. Raymond James advised their investors in a research report released on Sep 13, 2016.

On the company’s financial health, Natus Medical Inc reported $0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.36. The company had revenue of $96.00 million for the quarter, compared to analysts expectations of $92.71 million. The company’s revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.34 EPS.

Natus Medical Inc (BABY) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $41 and reached the intraday high at $41.0401. The bulls started the profit booking and pushed the shares to intraday low of $40.25. The trading session was marked by a volume range of 305,593 shares exchanging hands. The 52-week high of the shares is $51.05 and the 52-week low is $29.54. The market cap of the company stands at $1,351 M and there are 32,950,790 shares in public circulation.

In a different news, on Apr 28, 2016, Robert A Gunst (director) sold 5,000 shares at $34.61 per share price. According to the SEC, on Apr 28, 2016, Doris Engibous (director) sold 5,000 shares at $32.68 per share price. On Apr 28, 2016, Kenneth M Traverso (VP/GM Newborn Care) sold 7,459 shares at $33.56 per share price, according to the Form-4 filing with the securities and exchange commission.

Natus Medical Incorporated (Natus) is a provider of newborn care and neurology healthcare products and services used for the screening diagnosis detection treatment monitoring and tracking of common medical ailments in newborn care hearing impairment neurological dysfunction epilepsy sleep disorders and balance and mobility disorders. The Company offers two product families: Neurology which includes products and services for diagnostic electroencephalography and long term monitoring intensive care unit monitoring electromyography sleep analysis intra-operative monitoring and diagnostic and monitoring transcranial doppler ultrasound technology; and Newborn Care which includes products and services for newborn care including hearing screening brain injury thermoregulation jaundice management and various disposable products as well as products for diagnostic hearing assessment for children through adult populations and others.

Natus Medical Inc

Leave a Reply

Natus Medical Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Natus Medical Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.